Overview
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino acid peptide encoded within the mitochondrial genome. Discovered in 2015 by Dr. Changhan David Lee at USC, MOTS-c has rapidly emerged as a key metabolic regulator with profound implications for aging, obesity, diabetes, and exercise physiology.
Its primary mechanism involves activation of the AMPK pathway, leading to enhanced glucose uptake, improved insulin sensitivity, and increased fatty acid oxidation. MOTS-c levels decline with age, correlating with metabolic deterioration.
Exogenous MOTS-c administration in animal models has reversed high-fat diet-induced obesity, improved glucose tolerance, enhanced exercise capacity, and extended healthspan. Remarkably, MOTS-c translocates to the nucleus under metabolic stress to directly regulate gene expression.
This guide provides a comprehensive review of MOTS-c research, including its unique biology, metabolic effects, and current limitations in translating preclinical findings to human therapeutics.
Quick facts
- Mechanism
- Mitochondrial-derived AMPK activator and exercise mimetic
- Primary use
- Metabolic Enhancement & Longevity Research
- Evidence
- moderate
- FDA
- Not approved
- Route
- Subcutaneous injection (research)
- Typical results
- Improved insulin sensitivity and metabolic markers in preclinical models within 1–2 weeks
Chemical information
MOTS-c (C₉₉H₁₆₀N₂₅O₂₄S₂) is a mitochondrial compound with a molecular weight of 2,177.57 g/mol. Its structural characteristics underpin its biological activity in mitochondrial function and cellular energy.
How MOTS-c works
MOTS-c activates the AMPK signaling cascade by inhibiting the folate-methionine cycle, leading to accumulation of AICAR (ZMP), an endogenous AMPK activator. This triggers enhanced GLUT4 translocation, increased fatty acid β-oxidation, mitochondrial biogenesis, and suppression of de novo lipogenesis.
MOTS-c's indirect AMPK activation through folate cycle inhibition distinguishes it from direct AMPK agonists and may explain its more physiological metabolic effects. The resulting ZMP accumulation activates AMPK at the γ regulatory subunit.
Under metabolic stress, MOTS-c undergoes nuclear translocation where it interacts with antioxidant response elements (ARE), regulating genes involved in glutathione metabolism and NAD+ biosynthesis. This nuclear function is unique among mitochondrial-derived peptides.
In skeletal muscle, MOTS-c enhances insulin-independent glucose uptake via GLUT4. In adipose tissue, it promotes browning of white adipocytes via UCP1 upregulation, enhancing thermogenesis.
- AMPK activation: Activates AMPK through folate cycle inhibition and AICAR accumulation
- Nuclear translocation: Translocates to nucleus under stress to regulate gene expression
- GLUT4 mobilization: Enhances insulin-independent glucose uptake in skeletal muscle
- Mitochondrial biogenesis: Stimulates PGC-1α-mediated mitochondrial proliferation
- Adipose browning: Promotes white-to-brown fat conversion via UCP1
- Folate cycle modulation: Inhibits de novo purine biosynthesis
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability | Rapid SC absorption; peak plasma within 30–60 minutes | Endogenous levels decline ~15–20% per decade after age 30 |
| Onset of Action | Metabolic effects within hours; systemic benefits over days | Time to measurable clinical/biological response |
| Half-life | Estimated 4–8 hours (limited human PK data) | Determines dosing frequency |
| Duration of Effect | AMPK activation persists 12–24 hours | Functional activity beyond plasma clearance |
| Metabolism | Proteolytic degradation; renal clearance | Primary elimination pathway |
Dosing & administration
MOTS-c dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for MOTS-c is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Injection site reactions
- • Mild nausea
- • Transient hypoglycemia (rare)
- • Mild fatigue initially
- • Temporary appetite changes
Serious / potential risks
- • No serious adverse events in published animal studies
- • Theoretical hypoglycemia with diabetes medications
- • Unknown long-term effects
- • Potential folate metabolism interactions
- • Theoretical purine metabolism concerns
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Metformin | Both activate AMPK; additive glucose-lowering effects | Monitor closely; dose adjustment may be required |
| Insulin / Sulfonylureas | Enhanced glucose uptake may cause significant hypoglycemia | Avoid combination or use with extreme caution under medical supervision |
| Folate supplements | High-dose folate may attenuate MOTS-c effects | Generally safe; monitor if concerns arise |
| AICAR | Redundant AMPK activation; combination unstudied | Monitor closely; dose adjustment may be required |
Storage & handling
Lyophilized Powder
- • Store at -20°C long-term
- • Stable at 4°C for 3 months
- • Protect from light
- • Use desiccant
Reconstituted Solution
- • Reconstitute with bacteriostatic water
- • Refrigerate at 2–8°C
- • Use within 28 days
- • Do not freeze
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
MOTS-c is a mitochondrial compound with research interest in metabolic health, insulin sensitivity, exercise mimetic, longevity. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying mitochondrial function and cellular energy
- • Individuals interested in metabolic health under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Lee C, Zeng J, Drew BG, et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab (2015). doi: 10.1016/j.cmet.2015.02.009 PMID: 25738459
- [2] Reynolds JC, Lai RW, Woodhead JST, et al.. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline. Nat Commun (2021). doi: 10.1038/s41467-020-20790-0 PMID: 33479206
- [3] Kim KH, Son JM, Benayoun BA, Lee C.. MOTS-c translocates to the nucleus to regulate nuclear gene expression. Cell Metab (2018). doi: 10.1016/j.cmet.2018.06.008 PMID: 29983247
- [4] Kim SJ, Mehta HH, Wan J, et al.. Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging (2018). doi: 10.18632/aging.101373 PMID: 29608530